September 10, 2025MedicineOpen Access

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus

View Full Paper

Ask AI

Bookmark

Authors

CZChenxia ZhangFirst Affiliated Hospital Zhejiang University XCXinyue ChenNorth Sichuan Medical University ZHZehua HongJiangnan University

Discussion

Member takes

Implication

Retrospective analysis compares entecavir, tenofovir disoproxil, and tenofovir alafenamide efficacy in chronic hepatitis B patients, indicating TDF's superiority.

Key Points

At week 48, tenofovir disoproxil fumarate achieved 67.74% viral suppression, outperforming tenofovir alafenamide and entecavir.
Patients achieved HBV DNA <20 IU/mL with comparable hepatotoxicity normalization across all regimens.
High-density lipoprotein reductions were statistically significant in all treatments, with TDF showing the largest decrease.
TDF is preferred due to its superior antiviral efficacy and a comparably favorable safety profile in high viral load hepatitis B patients.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/68c243f6b210217d647a94bb https://doi.org/10.1097/md.0000000000043946

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis compares entecavir, tenofovir disoproxil, and tenofovir alafenamide efficacy in chronic hepatitis B patients, indicating TDF's superiority.

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparison of efficacy and safety of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate treatment in patients with high viral load of hepatitis B virus

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider